Biogen Idec (BIIB)
|
164.44
+4.14 (+2.58%)
|
|
|
|
BIIB additional information
Market Data powered by QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Filings and Fundamentals by Morningstar, Insiders by Vickers (USA) and SEDI(CDN), analyst ratings by Zacks.
BIIB Profile
•
Exchange
NASDAQ
•
Top Holders (By Fund)
Vanguard PRIMECAP Inv
Vanguard PRIMECAP Adm
Vanguard Capital Opportunity Inv
Vanguard Capital Opportunity Adm
Legg Mason ClearBridge Aggressive Gr I
Legg Mason ClearBridge Aggressive Gr B
Legg Mason ClearBridge Aggressive Gr C
Legg Mason ClearBridge Aggressive Gr A
Legg Mason ClearBridge Aggressive Gr FI
Legg Mason ClearBridge Aggressive Gr R
Vanguard PRIMECAP Adm
Vanguard Capital Opportunity Inv
Vanguard Capital Opportunity Adm
Legg Mason ClearBridge Aggressive Gr I
Legg Mason ClearBridge Aggressive Gr B
Legg Mason ClearBridge Aggressive Gr C
Legg Mason ClearBridge Aggressive Gr A
Legg Mason ClearBridge Aggressive Gr FI
Legg Mason ClearBridge Aggressive Gr R
•
Top Holders (By Family)
•
Executives
Dr. George A. Scangos Ph.D.
Chief Exec. Officer and Director
Mr. Paul J. Clancy
Chief Financial Officer and Exec. VP of Fin.
Dr. Douglas Edward Williams Ph.D.
Exec. VP of R&D
Mr. John G. Cox
Exec. VP of Pharmaceutical Operations & Technology
Mr. Steven H. Holtzman D.Phil.
Exec. VP of Corp. Devel.
Chief Exec. Officer and Director
Mr. Paul J. Clancy
Chief Financial Officer and Exec. VP of Fin.
Dr. Douglas Edward Williams Ph.D.
Exec. VP of R&D
Mr. John G. Cox
Exec. VP of Pharmaceutical Operations & Technology
Mr. Steven H. Holtzman D.Phil.
Exec. VP of Corp. Devel.
•
Employee Count
5,000
Special Offers
Competitors
BIIB earnings
Date
Actual
Expected
Prev Yr Qtr
10/25/2012
1.91
1.60
1.61
7/24/2012
1.82
1.56
1.36
5/1/2012
1.40
1.48
1.43
